High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant

Introduction

Sotrovimab is a monoclonal antibody that neutralizes SARS-CoV-2 by binding to a highly conserved epitope in the receptor binding domain of sarbecoviruses. It is one of the few approved monoclonals that retains activity against the Omicron BA.1 variant of concern (VOC).¹ Immunocompromised patients are at increased risk for a severe outcome of COVID-19 even after full vaccination against SARS-CoV-2. Indeed, the vaccination response is often reduced and can be completely absent in patients with combined T-cell and B-cell dysfunction.^2,3 Furthermore, prolonged viral replication and evolution has been described in the immunocompromised host.^4,5 Given the risk for a poor outcome, monoclonal antibody-based therapy is used to treat these patients. Especially during antibody monotherapy, viral evolution towards resistance against the antibody can be expected when replication is not sufficiently contained. Recently, the selection of mutations in the spike protein of the Delta VOC in 4 of 100 patients treated with sotrovimab was reported and all 4 were immunocompromised.⁶ Specifically, mutations at position 337 and 340 known to reduce susceptibility to sotrovimab were found.⁷ We studied viral evolution in 47 immunocompromised patients treated with sotrovimab for an infection with the Omicron VOC.

Methods

At Erasmus University Medical Center in Rotterdam, sotrovimab became available on January26^th,2022. It is used to treat immunocompromised patients infected with the SARS-CoV-2 Omicron VOC in the outpatient and inpatient setting. A SARS-CoV-2 PCR was performed at baseline and weekly thereafter, also after discharge until the PCR Ct-value was ≥30.⁸ Baseline and follow-up samples with a Ct-value <30 were sequenced on the Nanopore platform.⁹ Successful sequencing was defined as at least 90% of the genome covered with at least 30x coverage. The study was approved by the institutional review board under number METC2021-0309.

Results

Of the 47 patients treated, 24(51%) were male, the median age was 63(IQR 51 – 67), 31(66%) had undergone an organ transplantation, 13(28%) received B-cell depleting therapy and 5 treated with other immunosuppressives for auto-immune disease. 31 of 47(66%) patients were hospitalized when sotrovimab was given. In 30 patients, an IgG Spike antibody titer(Liaison IgG Trimeric S, Diasorin) was measured in the 30 days preceding sotrovimab therapy. Despite a history of at least 2 mRNA vaccinations in all and 3 or more in 24, Spike antibodies were negative in 18 and very low(<300 BAU/ml) in 25.

The median time to a Ct-value ≥30 was 15 days(IQR 7-22 days; range 3-36 days) but in 4 patients low PCR Ct-values persisted 29, 36, 49 and 49 days after treatment(Figure 1). Sequencing of at least one RNA sample was successful in 32 patients(25 BA.1 and 7 BA.2) and for 17 patients sequencing of a baseline as well as follow-up RNA samples was successful. In 6 of these 17 patients(35%), key spike mutations on positions 337 and 340 known to confer in vitro resistance to sotrovimab were found(Figure 1). This was the case for 4 of 25(16%) BA.1 infected patients and for 2 of the 7(29%) infected with BA.2. In a third BA.2 infected patient, a D796Y mutation was found but its impact on the sotrovimab IC50 is unknown. In all 4 patients with prolonged viral replication and BA.1 infection, mutations at position 337 or 340 of the Spike protein were found.

• Download figure
• Open in new tab

Figure 1:

Cyclic threshold value of patients treated with sotrovimab with a baseline RT-PCR and at least one follow-up RT-PCR available. The y-axis indicates the day of sotrovimab infusion. Red dots represent a Ct-value <30. Green dots represent a Ct-value of >30. Black dots represent the dead of a patient. Yellow dots represent a sequence showing new Spike mutations compared with the baseline Sequence.

Discussion

Following treatment with sotrovimab, spike mutations associated with reduced in vitro susceptibility were detected in 6 of 47 patients.⁷ Furthermore, more than 4 weeks after treatment with sotrovimab, 4 of them continued to have a high viral load. Despite the extremely low IC50 concentrations of sotrovimab against BA.1, genotypic resistance was detected after treatment in 4 of 25(16%) of the BA.1 infected patients. The high frequency of mutations found after treatment of patients with BA.2(43%) may be caused by the already 16-fold increased IC50 of sotrovimab against BA.2.¹⁰

Our observations show that viral evolution towards resistance can explain treatment failure in the majority of patients. Immunocompromised patients unable to clear SARS-CoV-2 despite antiviral therapy can serve as a source of new variants and should be closely followed until viral clearance is documented. Research is urgently needed to evaluate the value of direct acting antivirals in this patient group. Similar to the treatment of HIV, combination therapy may be required to reduce the risk for resistance.